XERS
Xeris Pharmaceuticals Inc
9.10$
-1.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 17.0% | 23.2% | 14.7% | 21.8% | 25.0% | 15.8% | 14.5% | 20.4% | 14.8% | 22.2% | 16.0% | 13.6% | 16.7% | |
| 83.0% | 76.8% | 85.3% | 78.2% | 75.0% | 84.2% | 85.5% | 79.6% | 85.2% | 77.8% | 84.0% | 86.4% | 83.3% | |
| 10.4% | 14.4% | 19.2% | 12.0% | 10.8% | 10.1% | 12.9% | 11.3% | 10.1% | 9.2% | 10.6% | 11.6% | 10.4% | |
| 77.2% | 84.6% | 94.4% | 83.2% | 82.9% | 66.8% | 73.2% | 62.1% | 62.5% | 55.4% | 63.9% | 66.3% | 62.1% | |
| 93.2% | 99.0% | 120.4% | 95.2% | 98.7% | 81.4% | 90.6% | 73.3% | 76.2% | 58.2% | 74.5% | 80.8% | 72.4% | |
| -10.2% | -22.2% | -35.1% | -17.0% | -23.8% | 2.8% | -5.1% | 6.3% | 9.0% | 19.5% | 9.5% | 5.6% | 10.9% | |
| 14.2% | 15.8% | 17.3% | 16.6% | 14.3% | 12.8% | 12.2% | 10.3% | 9.8% | 8.3% | 8.3% | 7.5% | 8.4% | |
| -25.9% | -30.7% | -45.9% | -29.7% | -35.1% | -8.5% | -15.3% | -2.7% | 0.8% | 12.9% | 2.7% | -33.8% | -5.1% | |
| -0.7% | -0.5% | 0.8% | 1.6% | -6.1% | – | – | – | – | – | – | – | – | |
| -25.2% | -30.2% | -46.7% | -31.2% | -29.0% | -8.5% | -15.3% | -2.7% | 0.8% | 12.9% | 2.7% | -33.8% | -5.1% | |
| -4.8% | -7.5% | -20.7% | -6.5% | -15.0% | 9.5% | 2.0% | 12.0% | 14.9% | 16.5% | 14.8% | -22.9% | 4.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.